AR052328A1 - Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer. - Google Patents

Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer.

Info

Publication number
AR052328A1
AR052328A1 ARP050104935A ARP050104935A AR052328A1 AR 052328 A1 AR052328 A1 AR 052328A1 AR P050104935 A ARP050104935 A AR P050104935A AR P050104935 A ARP050104935 A AR P050104935A AR 052328 A1 AR052328 A1 AR 052328A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
independently selected
group
Prior art date
Application number
ARP050104935A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR052328A1 publication Critical patent/AR052328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamidas, composiciones farmacéuticas que las contienen, y su utilizacion en la preparacion de un medicamento anticanceroso. Reivindicacion 1: Producto que comprende una cadena polihidroxílica de formula general (1) caracterizado por que (i) R1 se selecciona independientemente dl grupo constituido por alquilo, cicloalquilo, heterocicloalquilo, alquileno, heterocicloalquileno, arilo, heteroarilo, arilalquilo, heteroarilalquilo, arilalquileno, heteroarilalquileno, -C(R4)=N-O(R5), en el que R4 y R5 se seleccionan independientemente del grupo constituido por H, -alquilo C1-6, alquil C1-6-arilo, -alquil C1-6-heteroarilo ; (ii) R2 se selecciona independientemente del grupo constituido por las formula (2); R9 se selecciona del grupo constituido por H, COO(R10), CONH(R10), CO(R10), O(R10), en el que cada R10 se selecciona independientemente entre un par de electrones no enlazantes, H, -alquilo,-alquileno, -alquinilo, -alquilo halogenado, alquil-arilo, alquil-heteroarilo, -alquil-aril-heteroarilo, -arilo, -heteroarilo, cicloalquilo, en el que cada R10 está opcionalmente sustituido con al menos un sustituyente elegido entre OH, halogeno, -alquilo C1-4, -O-alquilo C1-4, -alquil C1-4- arilo, arilo, -alquil C1-4-heteroarilo, -heteroarilo, -N(CH3)2, -NH2, CONH2, los restos de formulas (3); y cada uno de los Rz se selecciona independientemente del grupo constituido por H, COO(R10), CONH(R10), CO(R10), R10, en el que cada R10 se selecciona independientemente entre -alquilo C1-4, - alquilo C1-4 halogenado, -alquil C1-4-arilo, -alquil C1-4-heteroarilo, en el que cada R10 está opcionalmente sustituido con un sustituyente elegido entre OH, halogeno, -alquilo C1-4, -O-alquilo C1- 4, -alquil C1-4-arilo, arilo, -alquil C1-4-heteroarilo, -heteroarilo; y R1', R2' y R3' se seleccionan independientemente entre H, R9 o unidos entre sí y con R9 pueden formar un ciclo alifático o aromático que comprende de 5 a 7 miembros, y de 0 a 3 heteroátomos elegidos independientemente entre O, S, N; (iii) R3 se selecciona del grupo constituido por - alquilo C1-6, -alquil C1-6-arilo, -alquil C1-6-heteroarilo, arilo, heteroarilo, arilalquileno, -heteroarilalquileno.
ARP050104935A 2004-11-29 2005-11-25 Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer. AR052328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412645A FR2878528B1 (fr) 2004-11-29 2004-11-29 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
AR052328A1 true AR052328A1 (es) 2007-03-14

Family

ID=34951749

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104935A AR052328A1 (es) 2004-11-29 2005-11-25 Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer.

Country Status (22)

Country Link
US (1) US7550453B2 (es)
EP (1) EP1819679A2 (es)
JP (1) JP2008521780A (es)
KR (1) KR20070091120A (es)
CN (1) CN101065362A (es)
AR (1) AR052328A1 (es)
AU (1) AU2005308710A1 (es)
BR (1) BRPI0516666A (es)
CA (1) CA2595305A1 (es)
CR (1) CR9114A (es)
EA (1) EA011392B1 (es)
FR (1) FR2878528B1 (es)
IL (1) IL183044A0 (es)
MA (1) MA29030B1 (es)
MX (1) MX2007006241A (es)
NO (1) NO20073026L (es)
PE (1) PE20061121A1 (es)
TN (1) TNSN07137A1 (es)
TW (1) TW200630343A (es)
UY (1) UY29236A1 (es)
WO (1) WO2006056696A2 (es)
ZA (1) ZA200704342B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2901556A1 (fr) * 2006-05-24 2007-11-30 Sanofi Aventis Sa Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation
FR2901554B1 (fr) 2006-05-24 2011-04-01 Sanofi Aventis 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
FR2901555A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation
CN101092384A (zh) * 2006-06-22 2007-12-26 中国科学院上海药物研究所 一类α－氨基－N－取代酰胺化合物、其组合物及用途
CN101456824B (zh) * 2007-12-11 2013-04-17 中国科学院上海药物研究所 α-氨基-N-取代酰胺化合物、包含该化合物的药物组合物及其用途
CN102264702B (zh) 2008-12-23 2015-03-25 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
AU2009331669B2 (en) 2008-12-23 2015-10-15 F. Hoffmann-La Roche Ag Dihydropyridone amides as P2X7 modulators
JP2012513435A (ja) 2008-12-23 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７調節薬としてのジヒドロピリドンアミド
BRPI0923498A2 (pt) 2008-12-23 2019-09-24 Hoffmann La Roche amidos de diidropiridona como moduladores de p2x7
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) * 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
CO5140099A1 (es) * 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
US6239127B1 (en) * 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
PT1282604E (pt) * 2000-05-11 2008-04-11 Novartis Ag Carbonatos e éteres caprolactâmicos substituídos e seu uso como agentes anti-tumorais
AU2002217020A1 (en) * 2000-11-14 2002-05-27 Novartis Ag Method for screening anti-proliferative compounds and inhibiting tumor growth
US6545148B2 (en) * 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
WO2005014574A1 (en) * 2003-07-25 2005-02-17 Novartis Ag Substituted lactams and their use as anti-cancer agents
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US7153846B2 (en) * 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
FR2878525B1 (fr) * 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2901555A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation
FR2901554B1 (fr) 2006-05-24 2011-04-01 Sanofi Aventis 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
FR2901556A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
BRPI0516666A (pt) 2008-09-16
EA200701172A1 (ru) 2007-10-26
TNSN07137A1 (en) 2008-11-21
CA2595305A1 (fr) 2006-06-01
MA29030B1 (fr) 2007-11-01
CN101065362A (zh) 2007-10-31
WO2006056696A2 (fr) 2006-06-01
US7550453B2 (en) 2009-06-23
FR2878528B1 (fr) 2008-05-16
US20070244087A1 (en) 2007-10-18
MX2007006241A (es) 2007-07-25
NO20073026L (no) 2007-08-27
PE20061121A1 (es) 2006-11-10
UY29236A1 (es) 2006-06-30
TW200630343A (en) 2006-09-01
AU2005308710A1 (en) 2006-06-01
ZA200704342B (en) 2008-07-30
EA011392B1 (ru) 2009-02-27
EP1819679A2 (fr) 2007-08-22
KR20070091120A (ko) 2007-09-07
FR2878528A1 (fr) 2006-06-02
WO2006056696A3 (fr) 2006-08-31
IL183044A0 (en) 2007-09-20
JP2008521780A (ja) 2008-06-26
CR9114A (es) 2008-01-21

Similar Documents

Publication Publication Date Title
AR052328A1 (es) Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
AR036175A1 (es) Derivados de la dolastatina 10, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos en la preparacion de medicamentos, procesos para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de dichos compuestos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR012315A1 (es) Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento.
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
NO20071067L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer.
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
AR084935A1 (es) Derivados de tipo azaindazol o diazaindazol como medicamentos
AR075587A1 (es) Derivados de bifenilo para el tratamiento de hepatitis c
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
PA8547701A1 (es) Nucleosidos 4 substituidos.
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR048021A1 (es) Derivados nucleosido fosfonato utiles en el tratamiento de infecciones de hiv.
AR036094A1 (es) Compuestos derivados de acido sulfonico, composicion farmaceutica y su uso en la preparacion de medicamentos
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
AR051349A1 (es) Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo.
ECSP024359A (es) Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante

Legal Events

Date Code Title Description
FB Suspension of granting procedure